|WHEN||June 11, 2016 @ 8:00am - 5:00pm|
|Date:||June 11th, 2016, 8:00am-5:00pm|
|Location:||Hilton, San Diego/Del Mar|
|Registration:||Main Conference: $30 for early birds (by June 8th), $50 for onsite registration, students and postdocs $10 off (The fees include parking at the hotel, program brochure, continental breakfast, coffee break, and lunch).
Bio-Partnering: $80 for early birds (by June 6th); $100 online regular registration closes on June 8th; No onsite registration. Fees include main conference, 1-on-1 partnering, program brochure, parking, continental breakfast, coffee breaks, and lunch.
|Online registration: https://www.123signup.com/register?id=prpbs|
|Organizer:||Sino-American Biotechnology & Pharmaceutical Professional Association|
As one of the nation’s premier innovation centers, San Diego biotech beach in recent years has witnessed mega-deals of mergers and acquisitions, highly successful IPOs, the groundbreakings of multiple state-of-the-art research institutes, and many recent launches of new drugs into the market. All these achievements are driven by many of the forward thinking leaders of our scientific community with great visions and strong determinations to help tackle the most daunting challenges of our time, and to translate scientific discoveries to clinical utilities to benefit mankind. Come to meet some of these visionary leaders at our upcoming SABPA Bio-Pharma conference to learn more about the latest breakthroughs in science and new trends in our industry, and to network with your peers. It is one of the biggest San Diego biotech events that you don’t want to miss.
Bio-Partnering Event: To ride on a successful Bio-Partnering pilot program from last year, SABPA will host the 2nd Pacific Bio-Partnering event. This event will provide a platform to arrange one-on-one meetings with the networking tool powered by partneringLITE – a product of EBD Group. This event aims to connect deputies from biotechnology and pharmaceutical companies in Southern California with pharmaceutical companies and/or investors from Asia for potential collaborations and strategic alliance opportunities. For more information, click “Bio-Partnering” tab.
|8:00 am||Exhibition (all day)
|8:00 am||Continental Breakfast & Registration
|8:30 am||Opening Remarks:
Yahu Liu, Ph.D., President, SABPA San Diego
Yi Liu, Ph.D., Chair, San Diego Bio-Pharma Conference
|8:45 am||2016 San Diego Bio-Pharma Achievement Award
Recipient: Faheem Hasnain, President and CEO, Receptos
Keynote Speech: The Receptos Story
|9:45 am||Title: Devising the New Arts of Drug Discovery at GNF
Gerald F. Joyce, M.D., Ph.D. Director, Genomics Institute of the Novartis Research Foundation
|10:15 am||Coffee Break/Networking
|10:45 am||Title: One Person’s Trash is Another Person’s Treasure
Ciara Kennedy, Ph.D. COO, Amplyx Pharmaceuticals, Inc.
|11:15 am||Title: The Power of Precision Medicine
Jonathan Lim, M.D., CEO and Chairman, Ignyta Inc.
|11:45 am||Title: Making Big Impacts by Stepping on Zhongshan to Start your Investment Journey of China’s Health Industry
Xia Lin,Vice President, Zhongshan Health Technology Park Development LTD (ZHTP)
Luncheon and networking
| 1:40 pm
|Beats Headphone Raffle
Afternoon session: Innovation and Entrepreneurship
Session Chairs: JC Xu, M.D., Ph.D., Director of Biology, Quanticel Pharmaceuticals
Guang Chen, M.D., Ph.D., Janssen Fellow, Scientific Director, Translational Research and Behavioral Pharmacology, J&J
|1:45 pm||Title: Innovation in Early Drug Discovery
Jay Lichter, Ph.D. Managing Director, Avalon Ventures
|2:15 pm||Title: Altering the immune response: An elixir for the 21st century?
Mitchell Kronenberg, Ph.D. President & Chief Scientific Officer La Jolla Institute for Allergy and Inflammation
|2:45 pm||Title: Manifest Destiny – A New Frontier through the Lenses of Wuxi
Yangzhou Wang, Ph.D., VP International Sales & BD Wuxi AppTec
|3:15 pm||Coffee Break/Networking
|3:45 pm||Plenary Discussion: Technology Transfer and Academia-Industry Collaboration
Modulator: Shuhag Ghosh, VP Global Solutions Marketing, Elsevier R&D Solutions
Anders Brunmark, Director
Peter Worland Head of external research, Celgene
Paul Roben, Associate Vice Chancellor, Innovation & Technology Commercialization, UC San Diego
Richard Glynne Executive Director, Strategic Alliances at Novartis Institutes for BioMedical Research
Jing-Shan “Jennifer” Hu Ph.D. Partner, Qiming US Healthcare Ventures
|4:45 pm||Title: Singapore-Chengdu Synergies in Biomedical Sciences
Joon-Woon Chong, VP Investment Promotion, Sembcorp Development, Sino-Singapore (Chengdu) Innovation Park Development Co., Ltd
|5:00 pm||Closing Remarks and Raffle Stephanie Shi, Ph.D., EVP, SABPA San Diego
Calling for sponsorship! Please contact email@example.com.
Confirmed Speakers, Panelists, Chairs, and Moderators :
|Faheem Hasnain, President and CEO, Receptos|
|Mr. Hasnain served as President, CEO and a Director of Receptos, Inc. from November 2010 to August 2015. Prior to joining Receptos, Mr. Hasnain was the President and Chief Executive Officer and a director of Facet Biotech Corporation, a biology-driven antibody company with a focus in multiple sclerosis and oncology. He held that position from December 2008 until the company’s acquisition by Abbott Laboratories in April 2010.
Previously, Mr. Hasnain was President, CEO and a Director of PDL BioPharma, Inc. from October 2008 until Facet Biotech was spun off from PDL BioPharma in December 2008. From October 2004 to September 2008, Mr. Hasnain served at Biogen Idec Inc., a biotechnology company specializing in neurological disorders, autoimmune disorders and cancer, most recently as EVP in charge of the oncology/rheumatology strategic business unit. Prior to Biogen Idec, Mr. Hasnain held roles with Bristol-Myers Squibb, where he was President of the Oncology Therapeutics Network, and for 14 years at GlaxoSmithKline and its predecessor organizations.
Mr. Hasnain is currently chairman of Tocagen, Inc. and Sente, Inc. and also serves on the board of directors of Kura Oncology, Inc. Prior board experiences include service on the board of directors of Ambit Biosciences Corporation, Seragon Pharmaceuticals, Somaxon Pharmaceuticals, Aragon Pharmaceuticals and, Tercica, Inc. Mr. Hasnain is a board member of BIO (a lobby and policy development organization for the biotech industry).
Mr. Hasnain received a B.H.K. and BEd. from the University of Windsor Ontario in Canada. He resides in San Diego, California with his wife Marie. They have two boys ages 27 and 25.
|Gerald F. Joyce, M.D. Ph.D., Director, Genomics Institute of the Novartis Research Foundation|
|Dr. Joyce has been the Director of the Genomics Institute of the Novartis Research Foundation (GNF) since 2014. He also is a member of the faculty of The Scripps Research Institute, where he maintains a laboratory in the Department of Chemistry. His research program has concerned the development of novel RNA and DNA enzymes and their potential application in clinical diagnostics and therapeutics. Dr. Joyce’s research also has led to the development of the first self-replicating RNA enzyme, which is capable of exponential growth and evolution. Prior to joining GNF, Dr. Joyce served as Dean of the Faculty at Scripps, Chair of the JASON scientific advisory group for U.S. national security, and member of the Technology Advisory Council of BP plc.
Dr. Joyce graduated with a B.A. from the University of Chicago in 1978 and both an MD. and PhD. from the University of California, San Diego in 1984. He carried out postgraduate medical training at Mercy Hospital in San Diego and postdoctoral research training at The Salk Institute.
Dr. Joyce is a member of the U.S. National Academy of Sciences, the Institute of Medicine, and the American Academy of Arts and Sciences. He is recipient of the U.S. National Academy of Sciences Award in Molecular Biology, the Hans Sigrist Prize from the University of Bern, and the U.S. National Academy of Sciences Award for Early Earth and Life Sciences.
|Ciara Kennedy, Ph.D. COO, Amplyx Pharmaceuticals, Inc.|
|Ciara Kennedy was appointed Chief Operating Officer of Amplyx Pharmaceuticals in October 2015, following a successful Series B financing ($50M). Amplyx is developing novel treatments for life-threatening invasive fungal infections. Prior to this appointment, Ciara served as Chief Operating Officer at Lumena Pharmaceuticals, until the company was acquired by Shire Pharmaceuticals in June 2014 for ~$400M and as Vice President, Head of Cholestatic Liver Disease at Shire for 1-year post acquisition.
As COO of Lumena, Ciara playe
A Ph.D. scientist by training Ciara received her doctorate at the Queen’s University of Belfast, Northern Ireland. Following which she relocated to the Burnham Institute, La Jolla, California, to continue her research in the field of apoptotic proteases. In 2004 Ciara became a member of the inaugural class of the Rady School of Management at UCSD, and graduated with a Masters of Business Administration in 2006.
|Jonathan Lim, M.D., CEO and Chairman, Ignyta Inc|
|Jonathan Lim co-founded Ignyta, Inc. (NASDAQ: RXDX) in August 2011 as Chairman, and subsequently joined the company full-time in July 2012 as President and CEO. Under his leadership, the company went public in 2013, has raised nearly $300 million from financings and corporate transactions with Teva and Lilly, and is focused on building a precision oncology company aspiring to eradicate residual disease in precisely defined patient populations by 2030. Dr. Lim is also a member of the Board of Visitors of the Moores Cancer Center at the University of California, San Diego, and an Advisory Council member of Stanford Bio-X, an initiative by Stanford University to foster interdisciplinary medical research. In March 2011, Dr. Lim co-founded and most recently served as Chairman and CEO of Eclipse Therapeutics, a Biogen Idec spinout. Eclipse was successfully sold to Bionomics Ltd (ASX:BNO) in a transaction that closed in September 2012, and Dr. Lim subsequently served as a member of the Board of Directors of Bionomics for three years, until November 2015. From May 2003 to December 2010, Dr. Lim was President, CEO, and a Director of Halozyme Therapeutics, Inc. (NASDAQ: HALO), where he led the company’s growth from a privately held startup with five employees to a publicly traded company with 140 employees. Under his leadership, the company went public and raised $300 million from financings and corporate partnerships with Roche and Baxter, achieved two U.S. FDA approvals, and built a deep pipeline of late stage clinical drug candidates. Dr. Lim’s prior experience includes management consulting at McKinsey & Company, NIH Postdoctoral Fellowship at Harvard/Dana Farber Cancer Institute, and two years of general surgery residency at New York Hospital-Cornell and Memorial Sloan Kettering Cancer Center.
Dr. Lim has BS and MS degrees from Stanford, an MD from McGill, and an MPH from Harvard.
|Jay Lichter, Ph.D., Managing Director, Avalon Ventures|
|Dr. Lichter is an experienced biotechnology and pharmaceutical business executive with 25 years of experience in management, scientific research, and business development. Throughout his career, Dr. Lichter has applied his exceptional combination of business acumen and deep technical knowledge to creating commercially successful biotech companies and identifying the commercial potential of scientific discoveries at their earliest stages. Dr. Lichter is the inventor on over 260 patents and patent applications for six Avalon portfolio companies, including more than 60 issued patents. Dr. Lichter has been either directly responsible for or participated in licensing or merger and acquisition deals valued in excess of $3 billion.
Dr. Lichter led Avalon X investments in AristaMD, Otonomy (NASDAQ: OTIC), SynthoRx, as well as the following investments in Sitari, Silarus, Thyritope, CadheRx, Adrenergics, Calporta and Iron Horse as part of the $495 MM strategic collaboration with GlaxoSmithKline. Dr. Lichter led Avalon investments in Afraxis, Carolus, Otonomy, Zacharon, RQx, Sova and Aratana (NASDAQ: PETX). He currently serves as a member of the board of directors for Avelas, AristaMD, SynthoRx, COI Pharmaceuticals, Carolus, Otonomy, RQx and Sova.
Dr. Lichter held postdoctoral positions in Human Genetics at Yale University and pharmacogenetics at DuPont Merck Pharmaceutical Co.
Dr. Lichter obtained his PhD in biochemistry from the University of Illinois at Chicago, and a BS from the Univ. of Illinois at Urbana-Champaign.
|Mitchell Kronenberg, Ph.D. President & Chief Scientific Officer La Jolla Institute for Allergy and Inflammation|
|Dr. Kronenberg received BA from Columbia University and a PhD from the California Institute of Technology in 1983, where he continued as a postdoctoral fellow in the laboratory of Dr. Leroy Hood. Dr. Kronenberg served on the faculty of the UCLA Department of Microbiology and Immunology from 1986-1997. He moved to the La Jolla Institute for Allergy & Immunology in 1997, and was appointed President in 2003. He is responsible for the leadership and overall administration of the Institute, which has grown to 24 faculties, a $55 million per year budget and more than 375 employees. He also is an Adjunct Professor of Biology at UC San Diego.
Dr. Kronenberg has co-authored more than 320 total publications, he was elected to be a Fellow of the American Association for the Advancement of Science and his other awards include an NIH Merit Award; Kroc Distinguished Professor in Medicine and Immunology at UC Davis, a Burroughs Wellcome Fund Visiting Professor at Harvard University, and in 2016 the San Diego Business Journal named him as San Diego’s most admired CEO among large nonprofit organizations.
Dr. Kronenberg’s research interests include antigen recognition by T lymphocytes, mucosal immunology, and inflammatory and autoimmune disease models. Some of his recent efforts have concentrated on Natural Killer T (NKT) cells, a unique T lymphocyte subpopulation that combines features of innate and adaptive immunity in responding to bacterial glycolipids. Another area of research interest concerns the role of TNF family ligands and receptors in regulating mucosal immune responses.
|Yangzhou Wang, Ph.D. VP International Sales & BD Wuxi AppTec|
|< img class=”alignnone size-full wp-image-5137″ src=”https://www.sabpa.org/wp-content/uploads/2016/06/9-Yangzhou-Wang_cropped_2016-Apr-09-1.jpg” alt=”9-Yangzhou Wang_cropped_2016-Apr-09″ width=”130″ height=”190″ />||Dr. Wang is a Vice President of International Sales and Business Development at WuXi AppTec. In his current role, Dr. Wang has the overall P&L responsibilities for WuXi’s Lab Testing Division (LTD), as well as other corporate development responsibilities. He was responsible for establishing LTD’s field commercial operations and leads a team of sales and technical sales professionals to drive the growth of WuXi preclinical and clinical testing businesses outside of China. Formerly, Dr. Wang served as an M&A/integration and corporate business development leader at Life Technologies/Applied Biosystems. Prior to that, he was a manager at the Hewlett Packard Laboratories and an assistant professor at the Hauptman Woodward Medical Institute/SUNY Buffalo.
Dr. Wang obtained his bachelor’s degree from Shandong University in China and his PhD in Cellular Molecular Biology from Roswell Park Cancer Institute in Buffalo New York.
|Shuhag Ghosh, VP Global Solutions Marketing, Elsevier R&D Solutions|
|Shuhag Ghosh is the Vice President, Global Solution Marketing for Elsevier’s R&D Solutions business. In this role, she is responsible for marketing and go-to- market execution of Elsevier’s data management solutions and services supporting Life Science R&D. Shuhag is also responsible for Elsevier’s Life Science Advisory Board which comprises representatives from R&D, R&D Informatics and Information Management across key pharma and biotech organizations. She has been closely involved in creating the longer term vision and strategic roadmap for the Life Science solutions portfolio in her earlier role as VP of Strategy and Business Development for the R&D Solutions business.
Prior to Elsevier, Shuhag was with A.T. Kearney, a global management consulting company, bringing over 12 years of experience in strategy development and marketing across industries including online media / information / publishing, working across India, Asia Pacific and North America. She holds a B.A. in Economics from Delhi University and an MBA from the Indian Institute of Management, Bangalore.
|Anders Brunmark, Director, External Innovation, Discovery Sciences, Janssen R & D, LLC, JNJ|
|Dr. Brunmark obtained his undergraduate in Chemistry at University of Lund and completed his PhD on quinones and free radical biochemistry at University of Linköping, Sweden. He held a faculty position at this University between 1988 and 1992. He did postdoctoral work on Immune recognition at the Department of Immunology at The Scripps Research Institute in La Jolla, CA between 1990 and 1994.
Dr. Brunmark joined J&J’s Pharmaceutical R&D organization in 1994 as group leader for protein expression and held a group leader position in Immunology Discovery 1999-2004. In 2004 Dr. Brunmark established an enabling technologies team at the La Jolla, California R&D site, comprising DMPK, PharmSci/formulations, Genomics, Compound Logistics, and High Throughput Screening functions. In 2012 he took a job as Scientific Director in Integrated Systems Biology. Since 2014, he is a Director in External Innovation in the Janssen R&D Discovery Sciences organization with primary responsibility for Western US and Canada.
Dr. Brunmark is an author on 48 papers, 3 book chapters, and inventor on 5 patents. Anders Brunmark’s research interests include development and application of new techniques for studying disease mechanisms and drug action both in vitro and in vivo.
|Peter Worland, Head of external research, Celgene.|
|Dr. Worland is Corporate VP at Celgene and has responsibility for External Research Programs. Over the last 6 years, he has been critically involved in defining the strategy and then execution to develop the network of corporate collaborations for Celgene. These have covered collaborations and quite different stages from early Discovery to those with Clinical Programs. Peter has been in industry for over 20 years working in biotechs at various stages from start-up to becoming established entities in addition to large pharma.
Dr. Worland received his BS (Hons) from the University of Western Australia and his PhD from the University of Melbourne, Australia.
|Paul Roben, Associate Vice Chancellor, Innovation & Technology Commercialization, UC San Diego|
|Dr. Roben was named Associate Vice Chancellor for Innovation and Commercialization at UC San Diego in June 2015.Working with the Vice Chancellor for Research, Dr. Roben is transforming the functions provided by the Technology Transfer Office, Industry Research Alliances, and Industry Contracting into an integrated organization to include patenting, strategic corporate research partnering and industry contracts. He oversees the Office of Innovation and Commercialization, which will establish a campus-wide innovation platform to build a systemic and sustainable innovation culture, create a vibrant regional ecosystem, and accelerate the commercialization of UC San Diego inventions.
Previously Dr. Roben was Sr. Director of Office Technology Development at the Salk Institute in La Jolla, working with multiple academic institutes to develop strategic processes to drive innovation alliances, and help translate their research programs into products for patients and society. He guided the formation of multiple new start-up companies and was responsible for the negotiation of a broad spectrum of technology licenses to industry. As a key member of Ireland’s Innovation Taskforce (2009 to present), he co-authored a national economic-development plan for Ireland, among other achievements.
Dr. Roben earned a BS in Biotechnology, as well as his PhD, at Dublin City University in Ireland, and studied as a Postdoctoral Fellow with Dr. Greg Silverman at UC San Diego.
|Richard Glynne, Executive Director, Strategic Alliances at Novartis Institutes for BioMedical Research|
|Dr. Glynne currently serves as the Director of Genetics and Neglected Diseases at the Genomics Institute of the Novartis Research Foundation (GNF). He received his PhD at Cancer Research UK (then ICRF), Lincoln’s Inn Fields. He went on to complete his postdoc at Stanford University, becoming one of the first people to apply microarray gene expression technology to a mammalian system.
In 1998, Dr. Glynne joined Eos Biotechnology, where he participated in a collaborative technology development effort to design a new microarray covering all of the genes that had been identified through the human genome sequencing effort. In 2002, he joined Phenomix, becoming VP of Genomics, where his group used forward mouse genetics to identify new genes regulating immunity and obesity. He set up collaboration with Genentech to run a mouse screen with an immunological focus.
In 2004, Dr. Glynne joined GNF where he became Executive Director of the Department of Genetics and Neglected Diseases. Here he managed the research efforts of approximately 45 people, including 15 PhDs, with research interests in drug discovery for infectious disease (Chagas disease, leishmaniasis, malaria, RSV, fungal infections), muscle regeneration, and immune modulation. The department also developed new target hypotheses using genetics and genomics platforms. In 2015, Dr. Glynne became an Executive Director in the Strategic Alliances group, responsible for evaluating external opportunities in Translational Medicine, Immunology and Immune-Oncology.
|Joon-Woon Chong, VP Investment Promotion, Sembcorn Development, Sino-Singapore (Chengdu) Innovation Park Development Co., Ltd|
|Mr. Chong leads the team for international investment promotion across Sembcorp Development’s projects in China, Vietnam and Indonesia. His primary responsibilities include industry positioning and strategic accounts engagement. Mr. Chong is currently driving the investment promotion and marketing efforts to develop a biomedical sciences ecosystem in the Chengdu project. In support of business development, Mr. Chong is also actively involved in the overall strategy and positioning to acquire new projects for Sembcorp Development.
Prior to joining Sembcorp in 2012, Mr. Chong spent 14 years in the Singapore Economic Development Board (EDB) with 7 years based out of EDB’s United States offices. His last stint in the United States was at the San Francisco office as Regional Director of Western Americas, overseeing EDB’s multiple offices responsible for investment promotion across the western half of the United States (including Texas), western Canada and Central America.
Mr. Chong was the Director of Electronics before he left the EDB. He led the team responsible for the planning, industry development and investment promotion efforts in Singapore’s electronics sector, which was the largest contributor of manufacturing investments for Singapore and accounted for more than 5% of Singapore’s GDP.
Mr. Chong graduated from the National University of Singapore with a Bachelor’s degree (Honours) in Electronics Engineering and a specialization in semiconductors. Mr. Chong enjoys wine, dine and good company.
|Xia Lin, Vice President , ZHONGSHAN HEALTH TECHNOLOGY PARK DEVELOPMENT LTD (ZHTP)|
|Ms LIN has worked in China’s health industry for nearly 25 years, including 4 years as clinical physician in hospital, 7 years as product manager and marketing specialist in Xi’an Janssen Pharmaceutical Ltd., and 14 years of business and innovation management in ZHTP.
Ms Lin organized The 1st Zhongshan Forum for Health and Development in 2006, and successfully updated this annual event as an innovative promotional platform to develop e-healthcare service industry by attracting companies and startups in fields of health data collections, data analysis and evaluation, medical inspection and testing, collaborative medical service, as well as health management, to form up a service chain for the digital health and medical service sector.
Ms Lin is now the vice president of ZHTP covers the business development of healthcare service industry. She has achieved well recognition for her professional experiences facilitating and enabling the business cooperation among the local administration, industry players and investment institutes, particularly for those medical service enterprises empowered by IT and IoT technologies.
|Jing-Shan Jennifer Hu, Ph.D. Partner, Qiming US Healthcare Ventures|
|Dr. Jing-Shan “Jennifer” Hu joined Qiming Venture Partners as Partner of Qiming US Healthcare Venture Fund in March 2016. She brings extensive experience in partnering, licensing, business development, R&D and management from three pharmaceutical multinational companies & two US biotech companies. Before Qiming, she was at Bayer Healthcare Pharmaceuticals as VP and Head of (External) Innovation Center China, responsible for building partnerships for Global Drug Discovery with organizations in Greater China. Prior to that, she was Director of Licensing &External Research at Merck&Co (MSD), heading early stage partnering/licensing efforts in Greater China for Worldwide Licensing &External Research on novel drug candidates and technologies.
She worked previously at Roche Palo Alto as Head of Functional Biology, at Affymetrix as Program Manager of Pharmacogenomics, and at Human Genome Sciences as Scientist of Protein Therapeutics VEGF-2 Project Leader. While working at biotech companies, she has been successful in partnering with various organizations, including biotech industry and academia such as Stanford University. Dr. Hu obtained her post-doctoral training at Harvard Medical School, PhD degree from Univ. of Texas Graduate School of Biomedical Sciences at MD Anderson Cancer Center, and BS degree in Biochemistry from Peking Univ.
The Receptos story by Faheem Hasnain
Devising the New Arts of Drug Discovery at GNF by Gerald F. Joyce
One Person’s Trash is Another Person’s Treasure by Mike Grey
The Power of Precision Medicine by Jonathan E. Lim
Altering the immune response: An elixir for the 21st century? by Mitchell Kroenberg
Manifest Destiny – A New Frontier through the Lenses of Wuxi by Yangzhou Wang
Singapore-Chengdu Synergies in Biomedical Sciences by Joon-Woon Chong
The Receptos Story
Receptos was a public biopharmaceutical company formed in 2009 with specific focus in immunology and metabolic disorders. Receptos’ lead program, Ozanimod, is a sphingosine 1-phosphate 1 and 5 receptor small molecule modulator in development for immune-inflammatory indications including inflammatory bowel disease and Relapsing Multiple sclerosis. Receptos was recently purchased by Celgene Corporation for $7.8b in August 2015.
Of note, Patents supporting Ozanimod were exclusively licensed to Receptos from The Scripps Research Institute (TSRI). Receptos is also developing RPC4046, an anti-interleukin-13 (IL-13) antibody for (EoE), an allergic/immune-mediated orphan disease, as well as other pipeline and pre-clinical stage compounds.
The Genomics Institute of the Novartis Research Foundation (GNF) provides a bridge between basic science and preclinical drug discovery for Novartis’ global research organization. With ~500 scientists and engineers, GNF takes an interdisciplinary approach to drug discovery that also draws upon its substantial expertise in high-throughput screening, highly-parallel cell-based assays, and other advanced automation technologies. Two FDA approved drugs originated at GNF: Zykadia (ceritinib) for treatment of non-small cell lung cancer, and Odomzo (sonidegib) for treatment of locally advanced basal cell carcinoma. Several additional GNF compounds are currently in human clinical trials. Two areas of special emphasis at GNF are immuno-oncology, focusing on local activation of the innate immune system, and regenerative medicine, focusing on activation of endogenous proliferation pathways to replenish functional cells. GNF also has launched three new strategic initiatives to explore new avenues for drug discovery. The Integrative Genomics initiative is pursuing a novel approach to identify new drug targets based on causal correlations between the levels of serum proteins and particular clinical traits. The RNA-Targeted Drug Discovery initiative includes a component of target discovery, where those targets are tertiary-structured functional RNAs, and aims to discover low molecular weight compounds that alter the function of those RNAs. The Molecularly-Targeted Drug Delivery initiative focuses on identifying and exploiting cellular addresses to enable preferential delivery of compounds to specific cell types, thereby improving safety and efficacy. All three initiatives, as well as the broader discovery efforts at GNF, depend on ongoing technological innovation to expand the art and science of drug discovery.
There is significant potential value in programs that have been shelved by pharma companies for strategic reasons. While a few companies have an active out-licensing program, many do not, so identifying and getting access to shelved programs is not straightforward. The presentation will review the experiences of 4 companies who have pursued a spin-out or out-licensing strategy:
- What worked and what didn’t
- Benefits and challenges
- Deal structures
Dr. Lim’s presentation will be on the Power of Precision Medicine, drawing from his personal experiences as a physician-turned- life sciences entrepreneur, investor, CEO, as well as his observations of the biotech industry.
The La Jolla Institute for Allergy & Immunology (LJI) is an independent not for profit research organization dedicated to studies of the immune system. Why focus on the immune system? Because cells of the immune system go everywhere in the body, protect us from deadly infections, but also over respond, which leads to a variety of chronic inflammatory and autoimmune diseases that are the scourges of the developed world. Therefore, by focusing on the immune system, and both the good and bad aspects of immune responses, we believe we can have the greatest impact on human health. I will summarize the history of LJI, which I have led since 2003, including its growth, some of the main research accomplishments, and products in development based on Institute discoveries. I will also give an over view of how cancer immune therapies are changing the medical treatment of tumors and some brief updates on research from
my lab on natural killer T cells; these cells have the potential to fight cancer.
With the exponential advances in genomic medicine and information technologies, pharmaceutical industry is at the cusp of major breakthroughs and poised to fundamentally transform healthcare. The global pharma market could reach $1.6 trillion by 2020, with over $499 Billion from China and other growth countries. Current China resembles the time of the Manifest Destiny in a number of ways. Through the lenses of WuXi AppTec, we share our story of a humble beginning to a >$3 Billion global CRO covering all major areas of pharmaceutical R&D. From a CRO’s perspective, we offer our optimism on the explosive nature of growth in China, and hope to convey a sense of unprecedented potential at this historical juncture. We encourage and welcome ambitious entrepreneurs and companies to explore and thrive in this new frontier of global transformation.
Fully owned by Sembcorp Industries, Sembcorp Development is undertaking master planning, land preparation and urban development in Asia. Sembcorp Development has three major parks in China, including Singapore-Sichuan High-tech Innovation Park (SSCIP), Wuxi-Singapore Industrial Park, Sino-Singapore Nanjing Eco Hi-Tech Island, and China-Singapore Suzhou Industrial Park. The four parks constitute the Sembcorp’s investment territory in China. As an industry leader with strong Singapore government background, Sembcorp undertakes SSCIP as the group’s latest investment. Sembcorp harnesses the opportunities in the Western Development Drive as well as the flourish bio-medical industry. Particularly, Chengdu has noticeable advantages in translation R&D institutions, pre-clinical trial animal resource & testing capabilities, as well as research hospitals’ clinical trial strength. As the VP of Sembcorp Development, Mr. Chong Joon Woon committed to introducing Singapore’s experience in developing biomedical industry into SSCIP to develop a biomedical sciences ecosystem and promote it to be China’s emerging biomedical R&D hub.
Healthcare industry in China has become a market of nearly USD 615 billion. In the past five years maintained a compound annual growth rate of more than 20%, and is expected to be doubled over the next five years, close to 10% per cent of Chinese GDP. This talk introduces the trends, influential factors and investment potentials in main sectors involve Medical Service, Medical Technology & Medical Instrument, Medicine & Bio-science, and Internet & Mobile Healthcare in China. ZHTP was founded in 1994 and has been the very first advanced and well established enterprise service provider in health industry.
ZHTP’s service includes comprehensive park management, c
onstruction, R&D support, capital & financing, incubation, and exchanges & cooperation. By 2015, ZHTP ‘s Total Industry Output reached USD6.48 bln., there are 203 enterprises settled, 85% of which, including 10 listed-in-public companies, are allocated in Bio-pharmacy, Medical equipment, Medical informatics, Medical logistics, Health foods, and Cosmetics. We are approaching for potential investment partners through flexible cooperation ways.
2nd Pacific Bio-Partnering (2016)
Saturday, June 11, 2016 9:30am-6:00pm
Hilton Del Mar/San Diego
Register Now: https://www.123signup.com/register?id=prpbs, to join the following organizations at SABPA 2nd Pacific Bio-Partnering on Saturday, June 11, 2016.
Investors: Alley Bridge Group, GF-Bay City Capital International Life Sciences USD Fund, Qiming US Healthcare Venture Fund, etc.
Companies: Abbvie, Kelun Pharma, CTTQ Pharma Group, Denovo Biopharma, etc.
Incubators: TEDA, Sino-Singapore (Chengdu) Innovation Park Development Co., 中山市健康科技产业基地发展有限公司, Songshan Lake, etc.
Pre-arrange one-on-one meetings with the networking tool powered by partneringLITE – a product of EBD Group. This event aims to help deputies from biotechnology and pharmaceutical companies in Southern California to explore potential partnerships and collaborations with pharmaceutical companies and/or investors from Asia and local.
- Engage in pre-event discussions and arrange valuable one-on-one meetings with biotechnology, pharmaceutical, and investment companies from San Diego and Asia to explore potential partnerships and collaborations.
- Now at minimal cost ($80), San Diego’s local entrepreneurs and life science companies are able to access global capital and market opportunities offered by fast growing Chinese pharmaceutical companies and cross border Asian investment firms in addition to local investors.
- Don’t miss this unique opportunity at the San Diego Bio-Pharma Conference to gain invaluable key investments for the startup or sustainable growth of your company!
- Each delegate will receive a personal registration link 6 weeks prior to the event.
Register Now: https://www.123signup.com/register?id=prpbs
When and Where?
- Saturday, June 11, 2016, 9:30am-6:00pm at Hilton Del Mar
- In parallel with the San Diego Bio-Pharma Conference (https://www.sabpa.org/2016/06/the-15th-san-diego-bio-pharma-conference-2016)
Who shall attend?
- Entrepreneurs and executives from local biotech and pharmaceutical companies
- Chinese pharmaceutical companies who are looking for collaboration opportunities
- Investors from local firms and China
What to do and to expect?
- Register to the Pacific Bio-Partnering (main BioPharma event + Pacific Bio-Partnering): https://www.123signup.com/register?id=prpbs
- Log-in to the partnering system with your private log-in info received through email sent by the meeting coordinator (firstname.lastname@example.org)
- Upload, edit and update your profile, objectives and your company/project/product profile
- Select to open your own available time slots for one-on-one meetings at the event on-site
- Search companies/projects/products/delegates within the system
- Send meeting requests or discussion topics to your potential collaborators
- Accept meeting invites from others if you would like to meet with them
- The system will automatically assign meeting time and table once your requests are accepted
- Be sure to print your meeting schedule before the event (printing may not be available on site) and attend the private face-to-face meetings at the event
Please click the link below for a step-by-step instruction:
For more information, please contact the partnering forum committee: email@example.com
Date: June 11th, 2015, 8:00am – 5:00pm
Location: Hilton, San Diego/Del Mar
|Main conference: $30 for early birds (by June 8th); $50 for onsite registration, students and postdocs $10 off (The fees include parking at the hotel, program brochure, continental breakfast, coffee break, and lunch).
Bio-Partnering: $80 for early birds (by June 6th); $100 online regular registration closes on June 8th; No onsite registration. Fees include main conference, 1-on-1 partnering, program brochure, parking, continental breakfast, coffee breaks, and lunch.
|Online registration: https://www.123signup.com/register?id=prpbs|
To create a platform for the entrepreneurs and VCs to mingle, a dinner reception (2016 San Diego Bio-Pharma Conference Reception or 生物医药年会招待晚宴) will be held after the 15th San Diego Bio-Pharma Conference at Hilton, San Diego/Del Mar. The reception will be by-invitation-only. To secure an invitation, scientists, entrepreneurs, and other professionals who have projects and ideas please submit a half-page project summary to firstname.lastname@example.org.
|SABPA, San Diego PO Box. 927631, San Diego, CA 92192-7631 U.S.A.|
|Donations (include sponsor payment)|
|Sponsorship Information||Please click here
for the details.
2015 BioPharma Event: https://www.sabpa.org/2015/06/the-14th-san-diego-bio-pharma-conference-2015/
2014 BioPharma Event: https://www.sabpa.org/2014/06/2014biopharma/
Events before 2013, please visit www.sdbiopharma.org